Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in th ...
March 15, 2023
– Dosing anticipated to start in the coming weeks – – Company remains on track for its planned data readouts from the Phase 1 ...Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 6, 2023
– Company expects to complete Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome in 2023 in order ...Stoke Therapeutics to Participate at Upcoming March Investor Conferences
February 27, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 27, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 7, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 7, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
January 9, 2023
– Additional safety and seizure frequency data from patients treated with multiple doses of STK-001 (45mg) anticipated in mid ...Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 4, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...